Landmark study: the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction Study (CAPRICORN)

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Beta-blockers are established for secondary prevention post-myocardial infarction (MI).
• Uncertainty existed regarding beta-blocker benefits with contemporary post-MI treatments.

Purpose of the Study:

• To evaluate the efficacy of carvedilol in patients with acute MI and left ventricular dysfunction.
• To assess if carvedilol provides additional benefit within modern post-MI care.

Main Methods:

• The Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial was a multicenter, randomized, placebo-controlled study.
• 1,959 patients with acute MI and ejection fraction ≤0.40 received carvedilol (25 mg bid) or placebo.
• Outcomes were assessed until 633 primary endpoints occurred, with a co-primary endpoint added due to lower-than-predicted mortality.

Main Results:

• A significant 23% reduction in all-cause mortality was observed with carvedilol.
• The co-primary endpoint (all-cause mortality or cardiovascular hospitalization) showed an 8% reduction, which was not statistically significant.
• Significant reductions were noted for cardiovascular mortality, nonfatal MI, and the composite of all-cause mortality or nonfatal MI.

Conclusions:

• Carvedilol demonstrated a significant reduction in all-cause mortality post-MI.
• Despite not reaching statistical significance for the revised primary endpoint, CAPRICORN provides valuable insights for beta-blocker use in early post-MI management.